

Improving Accessibility and Cost-Efficiency of Genetic Testing in Ovarian Cancer Diagnosis

Bokkers Lange*

Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands

Description

Genetic testing has revolutionized the field of healthcare, particularly in the realm of cancer diagnosis and treatment. In recent years, mainstream genetic testing has emerged as a promising approach, offering significant benefits to patients with ovarian cancer. By providing crucial genetic insights after diagnosis, this pathway has not only improved patient care but also demonstrated the potential to substantially reduce genetics-related healthcare costs. In this article, we explore the advantages of mainstream genetic testing in ovarian cancer and its impact on both patients and healthcare systems.

Traditionally, genetic testing for ovarian cancer was primarily conducted before or during surgery, with limited options available post-diagnosis. However, the advent of mainstream genetic testing has changed this landscape, enabling healthcare providers to offer genetic testing more frequently after diagnosis. This approach allows for a comprehensive evaluation of a patient's genetic profile, including germline mutations associated with hereditary forms of ovarian cancer, such as BRCA1 and BRCA2. By identifying genetic mutations, healthcare professionals can make informed decisions regarding treatment options, including targeted therapies and personalized interventions. Additionally, genetic testing aids in assessing the patient's risk of developing other types of cancer, guiding preventative measures and enabling proactive screening for affected family members. The availability of genetic information post-diagnosis empowers patients to make informed decisions about their healthcare journey, potentially leading to improved outcomes [1].

In addition to its impact on patient care, mainstream genetic testing presents a significant opportunity to reduce genetics-related healthcare costs. By offering genetic testing more frequently after diagnosis, healthcare providers can identify individuals who would have otherwise gone undetected through traditional screening methods. This proactive identification of genetic mutations enables early interventions and targeted treatments, potentially preventing disease progression and reducing the need for expensive and prolonged treatments. Mainstream genetic testing contributes to cost savings by identifying individuals who are not carriers of genetic mutations. This knowledge allows healthcare providers to streamline resources and focus on providing targeted care to individuals who are most likely to benefit from genetic-based interventions. By optimizing resource allocation, healthcare systems can allocate funds towards essential services, ensuring better overall patient care [2].

Despite the benefits of mainstream genetic testing in ovarian cancer care, certain barriers must be addressed to ensure widespread patient acceptance. High morbidity and mortality rates associated with ovarian cancer

can instill fear and anxiety in patients, potentially leading to a reluctance to undergo germline genetic testing. Healthcare providers must prioritize patient education and counseling, emphasizing the importance of genetic testing in guiding personalized treatment plans and improving outcomes. Moreover, understanding patient concerns and addressing ethical considerations associated with genetic testing is vital. By fostering open and empathetic communication, healthcare providers can build trust with patients, increasing their willingness to undergo genetic testing and embrace the benefits it offers.

Mainstream genetic testing has emerged as a transformative approach in the diagnosis and treatment of ovarian cancer. By offering genetic testing more frequently after diagnosis, healthcare providers can enhance patient care, tailor treatment plans, and reduce the burden of the disease. Simultaneously, this approach presents a significant opportunity to decrease genetics-related healthcare costs by identifying high-risk individuals and streamlining resources towards targeted interventions. Overcoming barriers and ensuring patient acceptance is crucial to fully harness the potential of mainstream genetic testing and provide the best possible care for individuals with ovarian cancer [3].

Germline genetic testing plays a vital role in diagnosing and managing ovarian cancer. By identifying hereditary gene mutations, healthcare providers can offer personalized treatment strategies and implement preventive measures for at-risk individuals. However, despite its importance, the high morbidity and mortality rates associated with ovarian cancer present a significant barrier to the widespread adoption of germline genetic testing. In fact, statistics indicate that approximately 10% of patients with epithelial ovarian cancer decline this valuable diagnostic tool. In this article, we explore the challenges posed by the disease's severity and patient reluctance, and discuss strategies to overcome these barriers for the benefit of ovarian cancer patients.

Ovarian cancer is often detected at advanced stages, leading to lower survival rates compared to other cancers. The high morbidity and mortality rates associated with the disease can create a challenging environment for offering germline genetic testing to patients. The physical and emotional burden of the diagnosis, coupled with concerns about treatment outcomes and prognosis, can overwhelm patients, making them hesitant to pursue additional diagnostic procedures. Fear and anxiety play a significant role in patients' decision-making process. The uncertainty surrounding genetic test results, potential implications for family members, and the impact on treatment choices can all contribute to patient reluctance. Overcoming these barriers requires a multi-faceted approach that addresses patient concerns, provides comprehensive education, and ensures empathetic support throughout the testing process [4].

One of the key strategies to mitigate the barrier of morbidity and mortality is to provide extensive patient education and counseling regarding the benefits and implications of germline genetic testing. Healthcare providers should prioritize clear communication, offering detailed explanations of the testing procedure, potential outcomes, and the impact on treatment decisions. By addressing patient concerns and providing accurate information, healthcare professionals can help alleviate anxieties and empower patients to make informed decisions. Genetic counseling can be a valuable tool in ensuring patient understanding and acceptance. Genetic counselors play a crucial role in guiding patients through the complexities of germline genetic testing, explaining the significance of identified gene mutations, and providing

*Address for Correspondence: Bokkers Lange, Department of Genetics, University Medical Center Utrecht, Utrecht, Netherlands, E-mail: bokkerslange@gmail.com

Copyright: © 2023 Lange B. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: 29 March, 2023, Manuscript No. Jgge-23-100003; Editor Assigned: 01 April, 2023, PreQC No. P-100003; Reviewed: 17 April, 2023, QC No. Q-100003; Revised: 22 April, 2023, Manuscript No. R-100003; Published: 29 April, 2023, DOI: 10.37421/2684-4567.2023.7.48

emotional support throughout the process. Engaging patients in open and empathetic conversations enables them to voice their fears and concerns, leading to a more informed decision-making process.

Another challenge in offering germline genetic testing is ensuring its accessibility and affordability for patients. The costs associated with genetic testing can act as a deterrent, particularly for those with limited financial resources or inadequate insurance coverage. Healthcare systems and policymakers should work collaboratively to promote affordable access to genetic testing services, ensuring that financial barriers do not prevent patients from benefiting from this crucial diagnostic tool. Furthermore, efforts should be made to enhance the availability of genetic testing in healthcare settings. Integrating genetic testing into routine care pathways for ovarian cancer patients can help streamline the testing process, reduce logistical hurdles, and increase patient acceptance. By making genetic testing a standard part of the diagnostic and treatment journey, healthcare providers can normalize its use and ensure that no patient is left behind.

The significant morbidity and mortality rates associated with ovarian cancer pose real challenges to the implementation of germline genetic testing. Patient reluctance, driven by fear and concerns about treatment outcomes, further compounds the issue. However, by prioritizing patient education, offering comprehensive counseling, and improving accessibility and affordability, healthcare providers can bridge the gap and promote the uptake of genetic testing in ovarian cancer patients. It is crucial for healthcare professionals, policymakers, and patient advocacy groups to collaborate in raising awareness about the benefits of germline genetic testing and addressing the barriers hindering its acceptance. By doing so, we can empower patients with the knowledge to make informed decisions, enable personalized treatment strategies and ultimately improve outcomes for individuals with ovarian cancer [5].

Acknowledgement

None.

Conflict of Interest

None.

References

1. Solomons, Nan M, Amanda E. Lamb, Frances L. Lucas and Eileen F. McDonald, et al. "Examination of the patient-focused impact of cancer telegenetics among a rural population: Comparison with traditional in-person services." *Telemed J E Health* 24 (2018): 130-138.
2. Sokolenko, Anna P., Tatiana N. Sokolova, Valeria I. Ni and Elena V. Preobrazhenskaya, et al. "Frequency and spectrum of founder and non-founder BRCA1 and BRCA2 mutations in a large series of Russian breast cancer and ovarian cancer patients." *BCR* 184 (2020): 229-235.
3. Kim, Eun Taeg, Ha Eun Jeong, Hyung Joon Yoon and Ki Hyung Kim, et al. "Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues." *Taiwan J Obstet Gynecol* 62 (2023): 66-70.
4. McDonald, Eileen, Amanda Lamb, Barbara Grillo and Lee Lucas, et al. "Acceptability of telemedicine and other cancer genetic counseling models of service delivery in geographically remote settings." *JOGC* 23 (2014): 221-228.
5. Crowther, Vanessa B., Sandra G. Suther, Juliet Davis Weaver and Clement K. Gwede, et al. "Exploring the association of physician characteristics to patient requests for genetic testing." *FPHR* 19 (2022): 5.

How to cite this article: Lange, Bokkers. "Improving Accessibility and Cost-Efficiency of Genetic Testing in Ovarian Cancer Diagnosis." *J Genet Genom* 7(2023): 48.